In the News

The authors discuss how inclusion of scientific surveillance techniques as part of centralized monitoring enhances the ability to monitor critical and non-critical data.

The authors explore the advancement of CAR-T therapies in China. While initial strides were primarily being made in the U.S. markets, can both foreign and domestic players win in China’s CGT market?

Susan Oliveria discusses how and why RWD and RWE are making an important impact on the development of medicines.

The authors examine how a new generation of extraction, identification and quantification tools – now recognized as approved methods by regulatory bodies – is changing the E&L testing landscape.

Michael Cohen comments on how digitizing, decentralizing and near-patient can reduce the environmental impact of clinical research.

Rose Blackburne discusses the huge opportunity for continued innovations that bring research closer to patients to help address health inequities.

Jill Sommerville discusses the challenges, opportunities and evolution of decentralized clinical trials.

Catherine Liloia and Benjamin Ziehr comment on the crucial role bioassays play in biologic drug development.

Lisa Dyment and Lloryn Hubbard weigh in on key areas of industry focus, including patient engagement and clinical trial diversity, for 2023.